
Vuokko Nummi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4853926/publications.pdf

Version: 2024-02-01



<u>ΥΠΟΚΚΟ ΝΙΙΜΜΙ</u>

#	Article	IF	CITATIONS
1	Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study. Haemophilia, 2020, 26, 891-897.	2.1	23
2	Platelets compensate for poor thrombin generation in type 3 von Willebrand disease. Platelets, 2020, 31, 103-111.	2.3	10
3	Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study. Haemophilia, 2021, 27, e253-e259.	2.1	10
4	Comprehensive reâ€evaluation of historical von Willebrand disease diagnosis in association with whole blood platelet aggregation and function. International Journal of Laboratory Hematology, 2018, 40, 304-311.	1.3	8
5	Monitoring onceâ€weekly recombinant factor <scp>IX</scp> prophylaxis in hemophilia B with thrombin generation assay and factor <scp>IX</scp> activity. International Journal of Laboratory Hematology, 2017, 39, 359-368.	1.3	6
6	Treatment outcomes in persons with severe haemophilia B in the Nordic region: The Bâ€NORD study. Haemophilia, 2021, 27, 366-374.	2.1	6
7	Weekly recombinant <scp>FIX</scp> prophylaxis for severe haemophilia B in normal clinical practice: data from <scp>UKHCDO</scp> and Finland. Haemophilia, 2017, 23, e240-e243.	2.1	3
8	Intravenous immunoglobulin treatment in a type 3 von Willebrand disease patient with alloantibodies and a lifeâ€ŧhreatening gastrointestinal bleed. Haemophilia, 2019, 25, e291-e293.	2.1	1
9	Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation. Haemophilia, 2021, 27, 793-801.	2.1	1
10	Factor IX antibodies and tolerance in hemophilia B in the Nordic countries – The impact of F9 variants and complications. Thrombosis Research, 2022, 217, 22-32.	1.7	1